Loading…
Pharming Group N.V. is projected to rise to $17.25 by 2027, a +26% move from its current price of $13.72. PHAR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $13.45 | $13.73 | $14.00 | +0.02% |
| Jul 14 | $13.35 | $13.73 | $14.12 | +0.05% |
| Jul 15 | $13.26 | $13.73 | $14.22 | +0.07% |
| Jul 16 | $13.20 | $13.74 | $14.30 | +0.10% |
| Jul 17 | $13.14 | $13.74 | $14.37 | +0.12% |
| Jul 18 | $13.09 | $13.74 | $14.43 | +0.15% |
| Jul 19 | $13.04 | $13.75 | $14.49 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.04 | $13.75 | $14.49 | +0.17% |
| Week 2 | $12.78 | $13.77 | $14.84 | +0.34% |
| Week 3 | $12.59 | $13.79 | $15.12 | +0.51% |
| Week 4 | $12.43 | $13.82 | $15.36 | +0.69% |
| Week 5 | $12.30 | $13.84 | $15.58 | +0.86% |
| Week 6 | $12.18 | $13.86 | $15.78 | +1.03% |
| Week 7 | $12.07 | $13.89 | $15.97 | +1.21% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pharming Group N.V. is a biopharmaceutical company that develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
Its lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K?
inhibitor.
Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. The company is categorized under Healthcare.
Pharming Group N.V. (PHAR) is a healthcare stock with a current price of $14.31 and a market capitalization of $1.01B. It is ranked 2533 by market cap.
Forecasts project a multi-year upside, beginning with 2026 where min $12.00, avg $14.31, max $19.69 and ROI 0 with sentiment NEUTRAL are shown. The trajectory then oils higher, with 2027 avg $18.02 and 2028 avg $21.11, followed by 2029 avg $22.13 and 2030 avg $25.22 (ROI 76.2) and continuing through 2031 $31.45, 2032 $35.63, 2033 $41.41, 2034 $46.55, and 2035 $47.82, culminating in 2040 avg $81.46 (ROI 469.3) and 2050 avg $154.19 (ROI 977.5). The overall sentiment remains BULLISH across the forecast.
These figures reflect the forecasted path for average prices and associated ROIs across the years listed.
A major floor 17.6% below — a decisive break under it would weaken the trend.
The nearest floor, 10.8% below — buyers have tended to step in here.
The nearest ceiling, 5.4% above — a clean break opens room to run.
A major ceiling 29.7% above — clearing it would confirm fresh momentum.
Key PHAR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PHAR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $14.19 | Sell | $14.02 | Sell |
| MA 10 | $13.90 | Sell | $13.86 | Sell |
| MA 20 | $13.37 | Buy | $13.59 | Buy |
| MA 50 | $13.46 | Buy | $13.84 | Sell |
| MA 100 | $14.93 | Sell | $14.51 | Sell |
| MA 200 | $15.62 | Sell | $14.54 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.73 | Neutral |
| Stoch RSI (14) | 49.75 | Neutral |
| CCI (20) | 61.00 | Neutral |
| Williams %R (14) | -34.29 | Info |
| MACD (12,26,9) | 0.14 | Buy |
| ROC (12) | 7.69 | Buy |
| Bollinger %B (20,2) | 0.70 | Neutral |
| Stochastic %K (14) | 65.71 | Neutral |
| TRIX (15) | 0.11 | Buy |
| Awesome (5,34) | 1.05 | Buy |
| Ultimate (7,14,28) | 55.17 | Neutral |
| Momentum (10) | 0.59 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 14.26 | Sell |
| ADX (14) | 16.67 | Neutral |
| ATR (14) | 0.25 | Info |
The 30-day technical picture is bullish. The RSI(14) is 60, and the price is trading near the resistance level of $14.31 with a nearby support at $12.24.
SMA50 stands at $13.66 and SMA200 at $15.63, with a 30-day price range of $12.41 to $16.51. The annualized volatility is 40%.
These indicators suggest positive near-term momentum, though the stock may test resistance near $14.31 while finding support around $12.24.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.00 | $13.72 | $18.77 | 0% | Neutral | |
| $14.07 | $17.25 | $22.14 | +26% | Bullish | |
| $16.22 | $20.28 | $26.77 | +48% | Bullish | |
| $16.76 | $21.30 | $28.76 | +55% | Bullish | |
| $18.74 | $24.15 | $33.22 | +76% | Bullish | |
| $23.14 | $30.22 | $42.26 | +120% | Bullish | |
| $26.02 | $34.40 | $48.82 | +151% | Bullish | |
| $29.77 | $39.79 | $57.24 | +190% | Bullish | |
| $33.14 | $44.77 | $65.21 | +226% | Bullish | |
| $33.91 | $46.27 | $68.18 | +237% | Bullish | |
| $55.16 | $78.74 | $121.86 | +474% | Bullish | |
| $96.94 | $149.25 | $248.34 | +988% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $12.00 | $13.72 | $16.59 | +0.00% |
| August 2026 | $12.03 | $14.10 | $16.89 | +2.73% |
| September 2026 | $11.91 | $14.03 | $16.95 | -0.46% |
| October 2026 | $12.26 | $14.50 | $17.64 | +3.34% |
| November 2026 | $12.71 | $15.09 | $18.46 | +4.07% |
| December 2026 | $12.80 | $15.26 | $18.77 | +1.11% |
Click any year to see its month-by-month PHAR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Pharming Group N.V.'s 2026 outlook centres on $13.72, within a $12.00 to $18.77 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, PHAR could reach as high as $22.14, with a base case around $17.25 and support toward $14.07 — roughly +26% from $13.72. Buyers look set to stay in control over this stretch.
Expect PHAR to range from $16.22 to $26.77 through 2028. The $20.28 average target implies a +48% move from current prices. That is up +18% on the projected 2027 average. Momentum favours further upside here.
The PHAR price prediction for 2029 points to an average of $21.30 (low $16.76, high $28.76) — a potential gain of +55% on today's $13.72. Buyers look set to stay in control over this stretch.
In 2030, PHAR is projected to trade between $18.74 and $33.22, averaging $24.15 — a potential gain of +76% from today's $13.72. That is up +13% on the projected 2029 average. Momentum favours further upside here.
Pharming Group N.V.'s 2031 outlook centres on $30.22, within a $23.14 to $42.26 range. That is up +25% on the projected 2030 average. That marks a +120% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, PHAR could reach as high as $48.82, with a base case around $34.40 and support toward $26.02 — roughly +151% from $13.72. Momentum favours further upside here.
Expect PHAR to range from $29.77 to $57.24 through 2033. The $39.79 average target implies a +190% move from current prices. That is up +16% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The PHAR price prediction for 2034 points to an average of $44.77 (low $33.14, high $65.21) — a potential gain of +226% on today's $13.72. Momentum favours further upside here.
In 2035, PHAR is projected to trade between $33.91 and $68.18, averaging $46.27 — a potential gain of +237% from today's $13.72. That is up +3% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Pharming Group N.V.'s 2040 outlook centres on $78.74, within a $55.16 to $121.86 range. That is up +70% on the projected 2035 average. That marks a +474% change versus current levels. Momentum favours further upside here.
By 2050, PHAR could reach as high as $248.34, with a base case around $149.25 and support toward $96.94 — roughly +988% from $13.72. Buyers look set to stay in control over this stretch.
Investing $1,000 in PHAR today (≈ 72.876205 PHAR) could be worth
$10,876.87
+$9,876.87 (+988%) by 2050 · US Dollar
Based on the average projected PHAR price of $149.25 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PHARwould be worth at today's price.
$1,000 invested in PHAR on Jul 10, 2025 (≈ 100 PHAR) would be worth
$1,372.19
+$372.19 (+37.2%) today · 1.37× · US Dollar
Based on a PHAR entry price of $10 vs. today's $13.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.77 | $996.51 | -0.3% |
| 1 month ago | $12.28 | $1,117.42 | +11.7% |
| 3 months ago | $17.09 | $802.92 | -19.7% |
| 6 months ago | $18.78 | $730.67 | -26.9% |
| 1 year ago | $10 | $1,372.19 | +37.2% |
| All time (5.0y) ago | $11.3 | $1,214.33 | +21.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PHAR forecast.
Our base-case forecast reaches $27.00 around 2031.
Implied market cap at $27.00: $1.91B
The multi-year forecast shows a strong upward trajectory. In 2030 the average price is projected at $25.22 with an ROI of 76.2 and bullish sentiment; by 2040 the average is $81.46 with an ROI of 469.3 and bullish sentiment; and by 2050 the average is $154.19 with an ROI of 977.5 and bullish sentiment.
The forecast also includes higher potential prices across the mid-term years, with 2040 and 2050 showing substantial upside versus today. These are estimates, not guarantees, and depend on market conditions and other factors.
Overall, the outlook is bullish for PHAR with meaningful long-term upside, tempered by typical investment uncertainty.
Tap a question to reveal the answer.
Min $19.36, Avg $25.22, Max $35.15; ROI 76.2; Sentiment BULLISH.
The forecast shows a bullish trajectory from 2027 onward, with Avg prices rising to $18.02 (2027), $21.11 (2028), $22.13 (2029), $25.22 (2030) and continuing through 2040 ($81.46) and 2050 ($154.19); ROI grows to 26 by 2027, 47.5 by 2028, 54.6 by 2029, 76.2 by 2030, 469.3 by 2040, and 977.5 by 2050.
Yes. The forecast max values include $51.35 (2032), $60.54 (2033), $68.96 (2034), $128.73 (2040), and $263.10 (2050). Minimums and averages also rise across years, with bullish sentiment throughout.
Current price $14.31; Market cap $1.01B.
RSI(14) 60; SMA50 $13.66; SMA200 $15.63; Support $12.24; Resistance $14.31; 30-day range $12.41–$16.51; Annualized volatility 40%.
Pharming Group N.V. Community Discussion
0Share your Pharming Group N.V. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.